On November 6, 2024, Sera Prognostics, Inc., a company specializing in pregnancy biomarker information, announced its financial results for the third quarter ending September 30, 2024. The announcement was made through a press release and is part of a Form 8-K report filed with the SEC. Sera Prognostics reported a third-quarter revenue of $29,000, a decrease from $42,000 in the same period of the previous year. Operating expenses increased by 8% to $8.9 million, with research and development expenses remaining flat at $3.5 million, and selling, general, and administrative expenses rising to $5.4 million due to investments in growth drivers. The net loss for the quarter was $7.9 million, up from $7.2 million in the prior year. The company highlighted several business developments, including the ongoing analysis of the PRIME study...Show More

On November 6, 2024, Sera Prognostics, Inc., a company specializing in pregnancy biomarker information, announced its financial results for the third quarter ending September 30, 2024. The announcement was made through a press release and is part of a Form 8-K report filed with the SEC. Sera Prognostics reported a third-quarter revenue of $29,000, a decrease from $42,000 in the same period of the previous year. Operating expenses increased by 8% to $8.9 million, with research and development expenses remaining flat at $3.5 million, and selling, general, and administrative expenses rising to $5.4 million due to investments in growth drivers. The net loss for the quarter was $7.9 million, up from $7.2 million in the prior year. The company highlighted several business developments, including the ongoing analysis of the PRIME study, an awareness campaign featuring TV programs, the launch of direct-to-consumer PreTRM testing, and the beta testing of a predictive analytics offering. Sera Prognostics also noted improvements in test scalability and unit economics due to a transition to ambient whole blood collection. The company's CEO, Zhenya Lindgardt, expressed optimism about the commercial potential following the anticipated publication of the full PRIME study results.